Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Photo Dynamic Therapy and Therapeutic Laser Technology. The company also designs, manufactures, and distributes super-pulsed cool laser technology for the treatment of pain for knees, nerves, muscles, and joints, as well as for in off-label use. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories. The company is also developing TLD-1433, an anti-cancer drug, which is in Phase 1B clinical trial for non-muscle invasive bladder cancer. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-416-6995273
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$2.26 million
Profitability
Miscellaneous
Employees20
Next Earnings Date5/29/2019 (Estimated)
OptionableOptionable
Theralase Technologies (CVE:TLT) Frequently Asked Questions
What is Theralase Technologies' stock symbol?
Theralase Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TLT."
When is Theralase Technologies' next earnings date?
Has Theralase Technologies been receiving favorable news coverage?
Headlines about TLT stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Theralase Technologies earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Theralase Technologies' key competitors?
What other stocks do shareholders of Theralase Technologies own?
Who are Theralase Technologies' key executives?
Theralase Technologies' management team includes the folowing people:
- Dr. Arkady Mandel, Interim CEO & Chief Scientific Officer
- Ms. Kristina Hachey, Chief Financial Officer
- Mr. Roger John Dumoulin-White, Director of Bus. Devel.
- Dr. Shawn Shirazi, Chief Exec. Officer of Drug
- Mr. Kipton Lade, Chief Exec. Officer of Device
How do I buy shares of Theralase Technologies?
Shares of TLT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Theralase Technologies' stock price today?
One share of TLT stock can currently be purchased for approximately C$0.54.
How big of a company is Theralase Technologies?
Theralase Technologies has a market capitalization of C$74.97 million and generates C$2.26 million in revenue each year. Theralase Technologies employs 20 workers across the globe.
What is Theralase Technologies' official website?
How can I contact Theralase Technologies?
Theralase Technologies' mailing address is 1945 Queen St E, TORONTO, ON M4L 1H7, Canada. The company can be reached via phone at +1-416-6995273.
MarketBeat Community Rating for Theralase Technologies (CVE TLT)
MarketBeat's community ratings are surveys of what our community members think about Theralase Technologies and other stocks. Vote "Outperform" if you believe TLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
